Bionet Therapeutics (ROCO:7808) FCF Margin %: -41.89% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7808 Bionet Therapeutics Corp ROCO:7808
12 GF Score
Price NT$31.00
! 2 Warning Signs
View Full Analysis

What is Bionet Therapeutics FCF Margin %?

Bionet Therapeutics ROCO:7808 12 FCF Margin % is -41.89% as of Dec. 2025. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Bionet Therapeutics ranks worse than 51.47% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bionet Therapeutics's Free Cash Flow for the six months ended in Dec. 2025 was NT$-38.6 Mil. Bionet Therapeutics's Revenue for the six months ended in Dec. 2025 was NT$92.2 Mil. Therefore, Bionet Therapeutics's FCF Margin % for the quarter that ended in Dec. 2025 was -41.89%.

As of today, Bionet Therapeutics's current FCF Yield % is -6.48%.

The historical rank and industry rank for Bionet Therapeutics's FCF Margin % or its related term are showing as below:

ROCO:7808' s FCF Margin % Range Over the Past 10 Years
Min: -861.52   Med: -210.79   Max: -91.06
Current: -91.06

During the past 4 years, the highest FCF Margin % of Bionet Therapeutics was -91.06%. The lowest was -861.52%. And the median was -210.79%.

ROCO:7808's FCF Margin % is ranked worse than
51.47% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs ROCO:7808: -91.06

Bionet Therapeutics FCF Margin % Related Terms

Bionet Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Bionet Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionet Therapeutics FCF Margin % Chart

Bionet Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 -861.52 -210.79 -91.06

Bionet Therapeutics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial -594.95 -202.12 -218.38 -163.79 -41.89

ROCO:7808 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Bionet Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bionet Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bionet Therapeutics's FCF Margin % falls into.


ROCO:7808
12GF Score
Bionet Therapeutics Corp ROCO:7808
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionet Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bionet Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-140.672/154.478
=-91.06 %

Bionet Therapeutics's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-38.605/92.163
=-41.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -41.89% mean?
Bionet Therapeutics (ROCO:7808) has a FCF Margin % of -41.89% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bionet Therapeutics and its competitors. According to the industry distribution chart, Bionet Therapeutics ranks #489 out of 950 companies in the Biotechnology industry, placing it in the top 51.5%.
Is Bionet Therapeutics' FCF Margin % too high?
Bionet Therapeutics' current FCF Margin % is -41.89%. Based on the distribution chart, Bionet Therapeutics ranks #489 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #489 out of 950 companies for FCF Margin %. This places Bionet Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bionet Therapeutics and its competitors. Bionet Therapeutics's current FCF Margin % is -41.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current FCF Margin % of -41.89%. The current FCF Margin % is -41.89%. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current FCF Margin % is -41.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bionet Therapeutics Business Description

Address No.28, Lane. 36 , Xinhu 1st Road, 1st Floor, Neihu District, Taipei, TWN, 11497
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score

Get the complete analysis for ROCO:7808

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.00
Price